Current Report Filing (8-k)
04 January 2022 - 6:22AM
Edgar (US Regulatory)
0001815974
false
0001815974
2022-01-03
2022-01-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 3, 2022
ANEBULO
PHARMACEUTICALS, INC.
|
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-40388
|
|
85-1170950
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
1415 Ranch Road 620 South, Suite 201
Lakeway, Texas
|
|
78734
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (512) 598-0931
|
|
N/A
|
(Former
name or former address, if changed since last report.)
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per share
|
|
ANEB
|
|
The
Nasdaq Stock Market LLC
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
CURRENT
REPORT ON FORM 8-K
Anebulo
Pharmaceuticals, Inc.
January
3, 2022
On
January 3, 2022, Anebulo Pharmaceuticals, Inc. issued a press release titled “Anebulo Pharmaceuticals Announces Initiation of Phase
2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication.” A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated by reference into this current report.
Item
9.01.
|
Financial
Statements and Exhibits.
|
(d)
Exhibits. The exhibit listed in the following Exhibit Index is filed as part of this current report.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ANEBULO
PHARMACEUTICALS, INC.
|
|
|
Dated:
January 3, 2022
|
By:
|
/s/
Rex Merchant
|
|
Name:
|
Rex
Merchant
|
|
Title:
|
Chief
Financial Officer
|
Anebulo Pharmaceuticals (NASDAQ:ANEB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anebulo Pharmaceuticals (NASDAQ:ANEB)
Historical Stock Chart
From Apr 2023 to Apr 2024